rt-PA治疗急性ST段抬高心肌梗死的疗效

目的：探讨急性ST段抬高心肌梗死（STEMI）患者应用瑞替普酶（rt-PA）静脉内溶栓的临床效果。方法：94例STEMI患者给予rt-PA静脉内溶栓，分析其溶栓再通率、再灌注心律失常情况、不良反应发生率和急性期病死率。结果：应用rt-PA静脉内溶栓的患者再通率88．3％；牙龈出血、恶心、呕吐等并发症发生率9．5％，无严重的出血并发症（如脑出血、消化道大出血等）；室性早搏等再灌注心律失常发生率73．4％。结论：应用rt-PA静脉内溶栓治疗AMI，再通率较高，出血并发症少。

Therapeutic effect of rt-PA in treatment of acute ST-segment elevation myocardial infarction

Objective： To explore the clinical effect of Reteplase （rt-PA） on intravenous thrombolysis in patients with acute ST-segment elevation myocardial infarction （STEMI）. Methods： Ninety-four cases with STEMI received rt-PA for in- travenous thrombolysis. Thrombolytic recanalization rate, reperfusion arrhythmia, the incidence of adverse reactions and a- cute phase mortality were analyzed. Results： Thrombolytie recanalization rate was 88.3% , the incidence of adverse reac- tions （including gingival bleeding gums, nausea, vomiting） were 9.5% but without serious bleeding complications （such as cerebral hemorrhage, gastrointestinal tract bleeding）. The reperfusion arrhythmia was 73.4%, such as premature ven- tricular beat. Conclusions： The thrombolytic reeanallzation rate is high by using rt-PA. It is safe and without serious bleed- ing complications.